1. Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound
- Author
-
Jung Min Chang, Eun Bi Ryu, Mirinae Seo, Woo Kyung Moon, Sun Ah Kim, and Ji He Lim
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Time Factors ,Multivariate analysis ,Receptor, ErbB-2 ,medicine.medical_treatment ,Breast Neoplasms ,Breast cancer ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Doubling time ,Radiology, Nuclear Medicine and imaging ,Breast ultrasound ,Mastectomy ,Triple-negative breast cancer ,Aged ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,Immunohistochemistry ,Tumor Burden ,Receptors, Estrogen ,Multivariate Analysis ,Disease Progression ,Female ,Ultrasonography, Mammary ,business ,Follow-Up Studies - Abstract
The aim of our study was to evaluate the tumour volume doubling time (TVDT) of molecular breast cancer subtypes by serial ultrasound (US). Sixty-six patients (mean age, 50 years; range, 29–78 years) with invasive breast cancer underwent initial and follow-up breast US examinations (at least three months apart) with no intervention. TVDT was determined using the tumours’ greatest dimensions in two orthogonal planes. The results were compared with clinical, imaging, and tumour variables and molecular subtypes (oestrogen receptor [ER]-positive, human epidermal growth factor receptor 2 [HER2]-positive, and triple negative) using a multiple linear regression analysis. TVDT exhibited a wide range (46–825 days; median, 141 days) with an overall mean of 193 ± 141 days and mean values of 241 ± 166 days for ER-positive tumours (n = 37), 162 ± 60 days for HER2-positive tumours (n = 12), and 103 ± 43 days for triple-negative tumours (n = 17) (P
- Published
- 2014
- Full Text
- View/download PDF